Full-Life Technologies has appointed Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD as Chief Scientific Officer. Dr. Heeger has held senior oncology clinical development positions at both large and emerging companies for more than 15 years. His work was instrumental to the development of Erbitux®, a monoclonal therapeutic antibody targeting EGFR, as well as the successful clinical development of other anti-cancer therapeutic antibodies, including targeted drug conjugates. Dr. ...